Found 21 clinical trials
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Etoposide in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma.
- 50 views
- 01 Dec, 2021
- 83 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …
- 997 views
- 26 Nov, 2021
- 114 locations
Gemcitabine Docetaxel and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
This phase I/II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine, docetaxel, and hydroxychloroquine, …
- 1 views
- 23 Jan, 2021
- 1 location
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
compared the activity of apatinib + IE in relapsed or refractory osteosarcoma in two sarcoma centers in China and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + IE
- 0 views
- 21 Jul, 2021
- 2 locations
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. …
- 16 views
- 18 Jul, 2021
- 1 location
Testing a New Immune Cell Therapy GD2-Targeted Modified T-cells (GD2CART) in Children Adolescents and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma The GD2-CAR PERSIST Trial
This phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory). T cells are infection …
- 0 views
- 24 Oct, 2021
- 1 location
A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
This is a phase 1/2 study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
- 0 views
- 26 Nov, 2021
- 8 locations
Cabozantinib With Topotecan-Cyclophosphamide
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. The names of the drugs are: Cabozantinib Topotecan Cyclophosphamide The names of the non-investigational supportive care drugs are: Filgrastim, pegfilgrastim, or a related growth factor.
- 0 views
- 07 Oct, 2021
- 2 locations
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
The purpose of this study is to see if nab-paclitaxel combined with gemcitabine prevents the formation or growth of tumors in participants with relapsed or refractory osteosarcoma, Ewing sarcoma
- 146 views
- 12 Sep, 2021
- 16 locations
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be …
- 0 views
- 18 Oct, 2021
- 8 locations